metastatic/advanced OC (mOC) - 1st line (L1) | metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | ||
mOC - L1 - all population | mOC - L1 - PDL1 positive | metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | |
immune chekpoint inhibitors | ||||
anti-PD-(L)1 | ||||
atezolizumab based treatment | ||||
atezolizumab plus SoC | IMagyn-050 ... | IMagyn-050 ... | ||
avelumab based treatment | ||||
avelumab alone | JAVELIN ovarian 200 ... | |||
avelumab plus pegylated liposomal doxorubicin | JAVELIN ovarian 200 ... | |||
avelumab plus SoC | JAVELIN Ovarian 100 | |||
Immune checkpoint association | ||||
nivolumab plus ipilimumab | NRG GY003 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -